This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
September 2026 revenue rises 13%, net profit rises 4%, margin narrows
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 4.8 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated revenue rose 13.2% year on year to Rs 31,104.14 lakh in the September 2026 quarter, while net profit increased 3.7% to Rs 3,109.95 lakh. The cash operating margin narrowed from 21.2% to 20.2%. For the first six months, revenue was Rs 59,836.49 lakh and net profit Rs 6,254.22 lakh, up 13.0% and 22.2%. A new 300-bed Raipur hospital was soft-launched in July 2026. The review found no material issue, and operating cash flow was positive at Rs 11,231.16 lakh.
Revenue and profit rose, but profit growth was modest and operating margin narrowed. The hospital launch and cash flow support the outlook.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹311.0 Cr | ₹274.7 Cr | +13.2% |
| Operating profit | ₹32.90 Cr | ₹31.72 Cr | +3.7% |
| Profit after tax | ₹31.10 Cr | ₹30.00 Cr | +3.7% |
| EBITDA margin | 17.6% | 18.4% | −0.8 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.